Table 1.

Categorization of cell lines based on phosphorylated ERK1/2 and AKT status MEK inhibitor (MEKi) sensitivity and oncogenic drivers

Tumor typeCell lineSensitive (IC50 <32 nmol/L)p-ERK1/2 Statusp-AKT StatusPTEN LossaDriver
TCCKinseySCLNone
OsteosarcomaMcKinleySCLMED12, PPM1D
OsteosarcomaVogelCLBRAF, MED12, TP53
TCCBlileySCABRAF
TCCTyler1SCABRAF, ATRX, ARID1A
TCCTyler2SCABRAF, ATRX, ARID1A
MelanomaCML-10C2SCAKRAS
Thyroid carcinomaCTACCAERBB2, TP53
Leukemia/LymphomaCLBL1CACCND3, TP53
Histiocytic sarcomaDH82CAYPTPN11
OsteosarcomaMorescoCANRAS, RAC1
HemangiosarcomaSBCATP53, PIK3CA, EP300
HemangiosarcomaCindySCCNone
TCCAngus1SCCKRAS
MelanomaJonesSCCNRAS, PTEN, ASXL1
Histiocytic sarcomaNikeSCCNF1
Melanoma17CM98CCKIT
MelanomaCML-6MCCNF1
HemangiosarcomaDEN-HSACCNone
Leukemia/LymphomaCLL1390CCYKDM6A, TET2, TP53
Leukemia/Lymphoma1771CCCIC
Mast cell tumorC2CCKIT, TP53
MammaryCMT12CCYKMT2C, TP53
Mast cell tumorBRMCTCCKIT, TP53, SETD2
OsteosarcomaGracieSAASRGAP3
Soft tissue sarcomaSTSA-1SAANF1
OsteosarcomaOS2.4AATP53
OsteosarcomaAbramsACYTP53
OsteosarcomaD-17LLKRAS (0.19)
Leukemia/LymphomaOSWLAASXL1, FBXW7, KMT2C, KMT2D, NF1, PTEN, SPEN, TP53
MelanomaParksLACDKN1A, EIF1AX, MED12
OsteosarcomaHMPOSLCYTP53
OsteosarcomaOSA8LCYKDM6A
  • Abbreviations: A, activated; C, constitutive; L, low expression/phosphorylation; S, sensitive.

  • aPTEN status was based on loss of its expression as assessed in Fowles et al. 2017.